Shareholders Equity (Details Textual) $ / shares in Units, $ in Thousands |
1 Months Ended | 6 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
|
Mar. 25, 2020
Employees
$ / shares
shares
|
Oct. 28, 2019
shares
|
May 31, 2017
$ / shares
shares
|
Jun. 30, 2020
USD ($)
$ / shares
shares
|
Dec. 31, 2019
Employees
consultants
$ / shares
shares
|
Nov. 30, 2017
shares
|
|
| Shareholders Equity (Textual) | ||||||
| Common stock, authorized | 60,000,000 | 60,000,000 | ||||
| Common stock, par value | $ / shares | $ 0.0001 | |||||
| Common stock, issued | 23,145,964 | 22,862,835 | ||||
| Common stock, shares outstanding | 23,140,264 | 22,862,835 | ||||
| Preferred stock, par value | $ / shares | $ 0.0001 | |||||
| Preferred stock, shares authorized | 1,000,000 | |||||
| Grant options | $ / shares | $ 914,741 | |||||
| Equity incentive plan, description | On May 5, 2020, the Board of Directors approved the grant of 79,000 options without consideration to four employees, under the 2019 Plan. These options were granted at an exercise price of $5.59 per share with a vesting period of four years. As of June 30, 2020, there are 28,041 shares available for issuance under the 2019 Plan. | |||||
| Total value of granted options | $ | $ 3,900 | |||||
| Issuance of warrants | 236,552 | |||||
| Warrants, description | a. 177,414 upon the filing of a patent application covering any Discovered Target or a Product (both as defined in the 2017 License Agreement). b. 118,277 upon achievement of the earlier of the following milestones by the Company: (i) execution of an agreement with a pharmaceutical company with respect to the commercialization of any of the Company's licensed technology or the Consulting IP or a Product (both defined in the 2017 License Agreement) or (ii) the filing of a patent application covering any Discovered Target (as defined in the 2017 License Agreement) or a Product. c. 59,139 upon completion of a Phase 1 clinical trial in respect of a Product (as defined in the 2017 License Agreement). | |||||
| Public warrants, description | ● in whole and not in part; ● at a price of $0.01 per warrant; ● at any time during the exercise period; ● upon a minimum of 30 days' prior written notice of redemption; ● if, and only if, the last sale price of the Company's Common Stock equals or exceeds $16.00 per share for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders; and ● if, and only if, there is a current registration statement in effect with respect to the shares of Common Stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption. | |||||
| Warrants expire years | 5 years | |||||
| License Agreement [Member] | ||||||
| Shareholders Equity (Textual) | ||||||
| Price Per Share | $ / shares | $ 0.0001 | |||||
| Warrants to purchase ordinary shares | 591,382 | |||||
| Minimum [Member] | ||||||
| Shareholders Equity (Textual) | ||||||
| Vesting period | 3 years | |||||
| Maximum [Member] | ||||||
| Shareholders Equity (Textual) | ||||||
| Vesting period | 4 years | |||||
| Yeda [Member] | ||||||
| Shareholders Equity (Textual) | ||||||
| Shares of issued warrants | 7,615 | |||||
| Founder [Member] | ||||||
| Shareholders Equity (Textual) | ||||||
| Shares of issued warrants | 2,974 | |||||
| New Incentive Plan [Member] | ||||||
| Shareholders Equity (Textual) | ||||||
| Common stock, par value | $ / shares | $ 0.0001 | |||||
| Grant options | $ / shares | $ 1,000 | |||||
| Equity incentive plan, description | The aggregate number of shares of Common Stock that may be delivered pursuant to the 2019 Plan will automatically increase on January 1 of each year, commencing on January 1, 2020 and ending on (and including) January 1, 2029, in an amount equal to four percent (4%) of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year. Notwithstanding the foregoing, the Board of Directors may act prior to January 1 of a given year to provide that there will be no January 1 increase for such year or that the increase for such year will be a lesser number of Common Stock than provided herein. | |||||
| Stock Options [Member] | ||||||
| Shareholders Equity (Textual) | ||||||
| Purchase of ordinary shares | 74,581 | |||||
| Grant options | $ / shares | $ 527,716 | |||||
| Grant approved | 814,700 | 704,669 | ||||
| Employees consideration | Employees | 65 | 22 | ||||
| Non-tradable options | 79,630 | |||||
| Consideration consultants | consultants | 2 | |||||
| Exercise price | $ / shares | $ 6.21 | $ 1.34 | ||||
| BiomX Israel [Member] | ||||||
| Shareholders Equity (Textual) | ||||||
| Exchange for common shares | 15,069,058 | |||||
| Shares outstanding, percentage | 65.00% | |||||
| Earnout shares, description | A. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2022 is greater than or equal to $16.50 per share. B. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2024 is greater than or equal to $22.75 per share. C. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2026 is greater than or equal to $29.00 per share. | |||||